Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Evans, Denise; van Rensburg, Craig; Govathson, Caroline; Ivanova, Olena; Rieß, Friedrich; Siroka, Andrew; Sillah, Abdou K.; Ntinginya, Nyanda Elias; Jani, Ilesh; Sathar, Farzana; Rosen, Sydney; Sanne, Ian; Rachow, Andrea; Lönnroth, Knut
• Is Part Of: Global health action. Volume 14:Issue 1(2020-2021)
• Publication Date: 2021-01-01
• Subjects: Catastrophic total costs -- income -- pre-treatment -- out-of-pocket -- TB sequelae; World health -- Periodicals; Global Health; World health; Periodicals; 362.1
• DOI: 10.1080/16549716.2020.1865625
• Languages: English
• ISSNs: 1654-9716

Abstract

ABSTRACT: The WHO developed a generic 'TB patient cost survey' tool and a standardized approach to assess the direct and indirect costs of TB incurred by patients and their households, estimate the proportion of patients experiencing catastrophic costs, and measure the impact of interventions to reduce patient costs. While the generic tool is a facility-based cross-sectional survey, this standardized approach needs to be adapted for longitudinal studies. A longitudinal approach may overcome some of the limitations of a cross-sectional design and estimate the economic burden of TB more precisely. We describe the process of creating a longitudinal instrument and its application to the TB Sequel study, an ongoing multi-country, multi-center observational cohort study. We adapted the cross-sectional WHO generic TB patient cost survey instrument for the longitudinal study design of TB Sequel and the local context in each study country (South Africa, Mozambique, Tanzania, and The Gambia). The generic instrument was adapted for use at enrollment (start of TB treatment; Day 0) and at 2, 6, 12 and 24 months after enrollment, time points intended to capture costs incurred for diagnosis, during treatment, at the end of treatment, and during long-term follow-up once treatment has been completed. These time points make the adapted version suitable for use in patients with either drug-sensitive or drug-resistant TB. Using the adapted tool provides the opportunity to repeat measures and make comparisons over time, describe changes that extend beyond treatment completion, and link cost survey data to treatment outcomes and post-TB sequelae. Trial registration : ClinicalTrials.gov: NCT032516 August 1196, 2017. Abbreviations : DOTS: Directly observed treatment, short-course; DR-TB: Drug-resistant tuberculosis; MDR-TB: Multi-drug resistant tuberculosis; NTP: National Tuberculosis Programme; TB: Tuberculosis; USD: United States Dollar; WHO: World Health Organization.